Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Acta Pharmacol Sin ; 44(7): 1500-1518, 2023 Jul.
Article in English | MEDLINE | ID: mdl-36639570

ABSTRACT

As a major class of medicine for treating the lethal type of castration-resistant prostate cancer (PCa), long-term use of androgen receptor (AR) antagonists commonly leads to antiandrogen resistance. When AR signaling pathway is blocked by AR-targeted therapy, glucocorticoid receptor (GR) could compensate for AR function especially at the late stage of PCa. AR-GR dual antagonist is expected to be a good solution for this situation. Nevertheless, no effective non-steroidal AR-GR dual antagonist has been reported so far. In this study, an AR-GR dual binder H18 was first discovered by combining structure-based virtual screening and biological evaluation. Then with the aid of computationally guided design, the AR-GR dual antagonist HD57 was finally identified with antagonistic activity towards both AR (IC50 = 0.394 µM) and GR (IC50 = 17.81 µM). Moreover, HD57 could effectively antagonize various clinically relevant AR mutants. Further molecular dynamics simulation provided more atomic insights into the mode of action of HD57. Our research presents an efficient and rational strategy for discovering novel AR-GR dual antagonists, and the new scaffold provides important clues for the development of novel therapeutics for castration-resistant PCa.


Subject(s)
Androgen Antagonists , Prostatic Neoplasms , Male , Humans , Androgen Antagonists/pharmacology , Receptors, Glucocorticoid/metabolism , Receptors, Androgen/metabolism , Androgen Receptor Antagonists/pharmacology , Prostatic Neoplasms/metabolism , Cell Line, Tumor
2.
Biochem Biophys Res Commun ; 498(3): 375-381, 2018 04 06.
Article in English | MEDLINE | ID: mdl-28709867

ABSTRACT

Ischemic injury in the heart is associated with death of cardiomyocytes and even after decades of research there is no appropriate therapeutic intervention to treat ischemic injury. The microRNA miR-34a is known to be induced in cardiomyocytes following ischemic injury. Another hallmark of ischemic injury is impaired glycolysis. The objective of the current study was to investigate the effects of short- and long-term exposure to hypoxia on miR-34a expression on apoptosis and regulation of key glycolysis metabolic enzymes. Both repeated short-term (30 min) burst of hypoxia with intermittent reoxygenation (30 min) as well as long-term (4 h) exposure to hypoxia followed by 6 h of reoxygenation robustly induced miR-34a levels. Hypoxia induced changes in cardiac permeability and localization of the channel protein connexin 34 as well as induced apoptosis as evident by levels of cleaved-caspase 3/7 and impaired cell proliferation. Hypoxia was also associated with decreased expression of key glycolytic enzymes hexokinase-1, hexokinase-2, glucose-6-phosphate-isomerase, and pyruvate dehydrogenase kinase 1. Attenuation of hypoxia-induced miR-34a by anti-miR-34a antagomir, but not a control antagomir, decreased miR-34a levels to those observed under normoxia and also inhibited apoptosis, potentially by rescuing expression of the key glycolytic enzymes. Cumulatively, our results establish that therapeutic targeting of miR-34a via antagomir might be a potent therapeutic mechanism to treat ischemic injury in the heart.


Subject(s)
Antagomirs/pharmacology , Cardiotonic Agents/pharmacology , Glucose/metabolism , Hypoxia/genetics , MicroRNAs/genetics , Myocytes, Cardiac/metabolism , Animals , Apoptosis/drug effects , Cell Hypoxia/drug effects , Cells, Cultured , Down-Regulation/drug effects , Hypoxia/drug therapy , Hypoxia/metabolism , Male , Myocytes, Cardiac/cytology , Myocytes, Cardiac/drug effects , Rats, Wistar , Up-Regulation/drug effects
3.
Biomed Pharmacother ; 83: 930-935, 2016 Oct.
Article in English | MEDLINE | ID: mdl-27522255

ABSTRACT

Patchouli alcohol (PA) is a tricyclic sesquiterpene extracted from a traditional Chinese herb pogostemonis herba. Literatures have proven that PA could inhibit inflammatory responses in various inflammatory disease models. However, whether PA could protect against atherosclerosis, a chronic vascular inflammation, is unknown. In this study, we sought to explore this issue in atherosclerosis-prone apolipoprotein E knockout mice fed an atherogenic diet, with or without daily PA intragastrical administration (40mg/kg). Our results showed that PA administration did not change plasma lipids metabolism, however, it significantly attenuated atherosclerotic plaque burdens in both the aorta and the aortic root. The lesional macrophage content, shown as Mac2 positive areas, was reduced, while the lesional smooth muscle cell and collagen content, shown as α-SMA positive areas and by Sirius red staining, respectively, was not affected in PA-treated mice, compared with non-treated controls. Aortic mRNA expression of macrophage inflammatory cytokines, including MCP-1, iNOS, IL-1ß, IL-6, CXCL9 and CXCL11, was also reduced in PA-treated mice. Therefore, we demonstrated that PA could attenuate atherosclerosis, possibly by inhibiting macrophage infiltration and its inflammatory responses.


Subject(s)
Atherosclerosis/drug therapy , Inflammation/pathology , Macrophages/pathology , Sesquiterpenes/therapeutic use , Animals , Aorta/drug effects , Aorta/pathology , Apolipoproteins E/deficiency , Apolipoproteins E/metabolism , Atherosclerosis/blood , Atherosclerosis/genetics , Atherosclerosis/pathology , Gene Expression Regulation/drug effects , Inflammation/genetics , Lipid Metabolism/drug effects , Lipid Metabolism/genetics , Lipids/blood , Macrophages/drug effects , Macrophages/metabolism , Mice , Mice, Knockout , Plaque, Atherosclerotic/pathology , Sesquiterpenes/pharmacology
4.
Exp Ther Med ; 12(1): 107-110, 2016 Jul.
Article in English | MEDLINE | ID: mdl-27347024

ABSTRACT

The present study reports a case of electrical storm occurring in a 43-year-old woman with dilated cardiomyopathy. The patient suffered from a cardiac electrical storm, with 98 episodes of ventricular tachycardia rapidly degenerating to ventricular fibrillation in hospital. The patient was converted with a total of 120 defibrillations. Recurrent ventricular tachycardia/fibrillation was initiated by premature ventricular beats. The patient did not respond to the use of amiodaronum. However, the administration of esmolol stabilized the patient's heart rhythm. A moderate dose of the ß-blocker esmolol, administered as an 0.5-mg intravenous bolus injection followed by an infusion at a rate of 0.15 mg/kg/min, inhibited the recurrence of ventricular fibrillation and normalized the electrocardiographic pattern. The results suggest that esmolol may be able to improve the survival rate of patients with electrical storm in dilated cardiomyopathy and should be considered as a primary therapy in the management of cardiac electrical storms.

5.
Hypertens Res ; 38(12): 813-20, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26224487

ABSTRACT

Autophagy is activated in hypertension-induced cardiac hypertrophy. However, the mechanisms and significance of an activated autophagy are not clear. This study was designed to determine the role of atorvastatin (ATO) in cardiac autophagy and associated benefits on cardiac remodeling and left ventricular function in spontaneously hypertensive rats (SHRs). Twenty-eight male SHRs at 8 weeks of age were randomized to treatment with vehicle (saline solution; SHR+V) or ATO (SHR+ATO; 50 mg kg(-1) per day) for 6 or 12 months. Age-matched male Wistar-Kyoto (WKY) rats were used as normotensive controls. Cardiac magnetic resonance was used to evaluate cardiac function and structure. Compared with WKY rats, SHRs showed significant left ventricle (LV) dysfunction, remodeling and increases in cardiomyocyte size, which were all attenuated by 6 and 12 months of ATO treatment. Compared with WKY rats, autophagy was activated in the hearts of SHRs and this effect was amplified by chronic ATO treatment, particularly following 12 months of treatment. Protein expression levels of microtubule-associated protein-1 light chain 3-II and beclin-1, the biomarkers of an activated cardiac autophagy, were significantly elevated in ATO-treated versus vehicle-treated SHRs and control WKY rats. Cardiac Akt and phosphorylated mammalian target of rapamycin (mTOR) expression were also increased in the hearts of SHR versus WKY rats, and this effect was attenuated by ATO treatment. These findings suggest that ATO-mediated improvements in LV function and structure in SHRs may be, in part, through its regulation of cardiac autophagy via the Akt/mTOR pathway.


Subject(s)
Atorvastatin/pharmacology , Autophagy/drug effects , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology , Proto-Oncogene Proteins c-akt/physiology , Signal Transduction/drug effects , TOR Serine-Threonine Kinases/physiology , Animals , Blood Pressure/drug effects , Male , Rats , Rats, Inbred SHR , Rats, Inbred WKY , Ventricular Remodeling/drug effects
6.
J Cardiovasc Transl Res ; 8(2): 89-95, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25701375

ABSTRACT

The study is to establish a novel method to determine the endothelial function in mouse carotid arteries in vivo by using high-resolution ultrasound images. Atherosclerosis in carotid arteries is induced in ApoE(-/-) mice with a Western diet. The ultrasound of the ventral neck generates clear pictures of the common carotid arteries. Acetylcholine at the range from 5 to 20 µg/kg/min (iv) is able to induce a dose-dependent relaxation as shown by the increased diameter of these normal mouse carotid arteries, which is impaired in atherosclerotic arteries. The endothelial function determined by ultrasound images in vivo matches well with that determined in isolated carotid arterial rings in vitro. All animals survived after the endothelial function measurement. In this study, we have established a standard method to determine the mouse endothelial function in vivo. It is a reliable, safe, and survival method that could be used repetitively in mouse arteries.


Subject(s)
Carotid Artery Diseases/diagnostic imaging , Carotid Artery, Common/diagnostic imaging , Endothelium, Vascular/diagnostic imaging , Acetylcholine/pharmacology , Animals , Apolipoproteins E/deficiency , Apolipoproteins E/genetics , Carotid Artery Diseases/physiopathology , Carotid Artery, Common/drug effects , Carotid Artery, Common/physiopathology , Disease Models, Animal , Dose-Response Relationship, Drug , Endothelium, Vascular/drug effects , Endothelium, Vascular/physiopathology , Male , Mice, Knockout , Predictive Value of Tests , Reproducibility of Results , Ultrasonography , Vasodilator Agents/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...